SGLT1 is required for the survival of triple‐negative breast cancer cells via potentiation of EGFR activity - Liu, Huiquan; Ertay, Ayse; Peng, Ping; Li, Juanjuan; Liu, Dian; Xiong, Hua; Zou, Yanmei; Qiu, Hong; Hancock, David; Yuan, Xianglin; Huang, Wei‐Chien; Ewing, Rob M.; et al. (Molecular oncology, 2019)
Keywords: AKT protein; Antibiotics; Breast cancer; Cancer cells; Cancer therapies; Cell Line, Tumor; Cell Survival; Chemotherapy; Colorectal cancer; EGFR; Epidermal growth factor; Epidermal growth factor receptors; ErbB Receptors - genetics; ErbB Receptors - metabolism; Ethylenediaminetetraacetic acid; Female; Gene expression; Glucose transport; Homeopathy; Humans; Intracellular; Kinases; Ligands; MAP Kinase Signaling System; Materia medica and therapeutics; Medical prognosis; Medical research; Neoplasm Proteins - genetics; Neoplasm Proteins - metabolism; Prostate cancer; Protein transport; R&D; Research & development; Response rates; Science; SGLT1; Signal transduction; Sodium; Sodium-glucose cotransporter; Sodium-Glucose Transporter 1 - genetics; Sodium-Glucose Transporter 1 - metabolism; Therapeutics; Triple Negative Breast Neoplasms - genetics; Triple Negative Breast Neoplasms - metabolism; Triple Negative Breast Neoplasms - pathology; triple‐negative breast cancer; Tumors; Xenografts; China; United States--US; triple-negative breast cancer; SGLT1; EGFR